Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective disruption of DNMT1/ELK1 interactions induces DGKI re-expression and promotes temozolomide sensitivity of MGMTmethylated/DGKImethylated glioblastoma

30 Aug 2025

Abstract excerpt

DNA methyltransferase (DNMT) inhibitors are emerging as a promising class of agents for personalized and targeted cancer therapy, particularly in malignancies with limited therapeutic options such as glioblastoma (GB). In GB, the MGMT/DGKI methylation profile serves as a biomarker for stratifying patients by treatment response. Specifically, the MGMT methylated /DGKI unmethylated profile is associated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40886022
DOI: 10.1186/s13148-025-01943-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Selective disruption of DNMT1/ELK1 interactions induces DGKI re-expression and promotes temozolomide sensitivity of MGMTmethylated/DGKImethylated glioblastomaPMID 40886022Read ↗

Targeting glioma stem‐like cell survival and chemoresistance through inhibition of lysine‐specific histone demethylase KDM 2BSemantic proximity Read ↗

Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastomaSemantic proximity Read ↗

Targeting of Histone Demethylases KDM5A and KDM6B Inhibits the Proliferation of Temozolomide-Resistant Glioblastoma CellsSemantic proximity Read ↗

Epigenetic Deregulation of the Histone Methyltransferase KMT5B Contributes to Malignant Transformation in GlioblastomaSemantic proximity Read ↗

Histone demethylase KDM4B accelerates the progression of glioblastoma via the epigenetic regulation of MYC stabilitySemantic proximity Read ↗

Multiplex-inhibitor bead mass spectrometry reveals differential kinome signatures in newly diagnosed and recurrent glioblastomaSemantic proximity Read ↗

Regulation of<i>KEAP1</i>expression by promoter methylation in malignant gliomas and association with patient’s outcomeSemantic proximity Read ↗

Temozolomide in the Era of Precision MedicineSemantic proximity Read ↗

Lsd1 as a therapeutic target in Gfi1-activated medulloblastomaSemantic proximity Read ↗

Structural mimicry of UM171 and neomorphic cancer mutants co-opts E3 ligase KBTBD4 for HDAC1/2 recruitmentSemantic proximity Read ↗

Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1β/VEGFA signallingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.